BMR release BMR: Yesterday’s news from Sona Nanotech(SONA, CSE) disappointed investors (short-term traders in particular) who were hoping (expecting) by now to see 3rd party validation of the company’s Rapid Response Lateral Flow Test. The stock fell another 39 cents to $1.20. However, keep in mind the following: SONA has received confirmationfrom an independent laboratory that its test achieved a positive response to a recombinant whole spike protein control reagent specific to SARS-CoV2 and matched the limit of detection (LOD) achieved in its own labs. In-house analytical testing has indicated a very high level of specificity to COVID-19, with no false positives being generated;SONA has already tested the prototype in a hospital laboratory environment with live, COVID-19patient samples, achieving positive results (April 14 news). Expanded testing with live virus is a critical final step in the validation process.For that, SONA is engaging a leading American laboratory (ironic in the sense that the Canadian government awarded SONA a $4.1 million grant through NGen, Canada’s advanced manufacturing supercluster, to develop and commercialize its Rapid Response Test);“Formal clinical study/trial” verbiage in yesterday’s news may have thrown off some investors who normally think of “clinical trials” in terms of lengthy time periods. In the context of this type of testing, as per FDA rules, a “clinical trial” typically spans just days, not weeks or months, and involves a very short hospital validation. SONA is targeting completion of validation by the end of the month;Demand for an accurate rapid response lateral flow test from governments across the globe remains VERY high, while we’re also told by industry insiders that demand from the private sector is skyrocketing. In other words, SONA remains on track to capture a huge market and exceed our conservative estimate of 8 million unit sales upon near-term 3rd party validation;The extra time it has taken to complete rigorous testing, to ensure maximum performance of the device in terms of both quality and accuracy, stands to benefit SONA and its shareholders immensely.